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ABSTRACT Discerning a mechanistic understanding of the cause-and-effect relationships between
chromatin post-translational modifications (PTMs) and DNA accessibility for replication, transcription,
and repair is an elusive goal being pursued using molecular and cellular biology, biochemistry, and more
recently chemical inhibition. Chemical intervention of the chromatin-associated complexes that regulate
PTM maintenance and chromatin structure faces numerous challenges due to the broad surface-groove
interactions between many of these proteins and histones; yet, the increasing interest in understanding
chromatin-modifying complexes suggests tractable lead compounds will be critical for elucidating the
mechanisms of chromatin dysregulation in disease states and validating the druggability of these domains.
Peptides and peptidomimetics afford several advantages to efficient inhibitor development including a
rational starting point, modular assembly, and retention of secondary structure. Numerous peptide tech-
nologies have been employed in the chromatin field to characterize substrate interactions, evaluate ligand
selectivity, and optimize potent peptidomimetic inhibitors. We describe the progress and advantages of
these efforts, and provide a perspective on their implications for future chemical probe and drug discovery
efforts. Drug Dev Res 78 : 300-312, 2017. VC 2017Wiley Periodicals, Inc.
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INTRODUCTION
Innovative chemical strategies to interrogate pro-
tein function have irrevocably altered how we understand
biological systems. Chemical tools contribute to an under-
standing of target-specific biology, but the extent to which
they do so is fully dependent on the quality of the chemi-
cal tools [Bunnage et al., 2013; Frye, 2010; Arrowsmith
et al., 2015]. Ultimately, high-quality chemical probes
must have nanomolar or better target affinity, well-
characterized selectivity, and activity in cells. These
probes do not replace modern genetics or molecular biol-
ogy, nor is that the intent. Instead, they complement
these approaches by disrupting (enhancing or inhibiting)
a specific function or interaction of the target protein. In
contrast, genetic mutations and small interfering RNA
(siRNA) knockdowns or gene knockouts may ablate sev-
eral activities of the target and can prevent participation
in, or the formation of, larger protein complexes. The
chemical probe is intended to exquisitely elucidate the
role of an individual protein modality in a temporally
resolved and dose-dependent manner [Frye, 2010].
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The stringent standards for chemical probe status
require a significant upfront investment. While early
stage hit discovery often focuses on screening diverse
and purchasable compound libraries, the chemical space
occupied by these libraries tends to be biased toward
pockets of more traditional, “druggable” targets (i.e.,
enclosed and hydrophobic) [Hopkins and Groom,
2002]. Often designed around aromatic scaffolds, the
inherent “drug-like-ness” and lack of conformational
complexity within these libraries frequently proves inad-
equate for inhibition of common protein–protein inter-
actions (PPIs) [Tsomaia, 2015]; yet, constructing
libraries of structurally diverse small molecules with
complex, three dimensional features would be high risk,
time consuming, and expensive [Hann and Oprea,
2004]. In contrast, peptidic and peptidomimetic ligands
can adopt unique 3D conformations, naturally mimick-
ing PPIs and promoting induced-fit binding through
specific hydrogen bond contacts of the amide backbone
and complimentary side group functionalities.
The low-cost and ease of peptide synthesis, accom-
panied by a variety of technological advances in screen-
ing, position peptidic ligands as an intriguing alternative
to traditional small molecules for PPI inhibitor discovery
[Lam et al., 1997; Smith and Petrenko, 1997; Frank,
2002; Takahashi et al., 2003]. Moreover, when a PPI has
been structurally characterized, peptide optimization
may proceed from a rational starting point. For instance,
structural characterization of the interaction between an
a-helix of p53 and MDM2 [Kussie et al., 1996] spurred
extensive efforts in peptide and peptidomimetic ligand
development for MDM2. Novartis employed combina-
torial chemistry, structure-activity relationship (SAR)
studies, and structure-based design (SBD) to evolve a
low affinity 12-mer peptide of p53, first into a cellularly
active, sub-micromolar 12-mer ligand, and then into a
single-digit nanomolar, non-natural peptide inhibitor of
MDM2 [Che`ne et al., 2000; Garcia-Echeverria et al.,
2000; Sakurai et al., 2006; Furet et al., 2012]. Peptide
SAR subsequently contributed to an understanding of
the PPI hotspots between p53 and MDM2 that were
found to be targetable by small molecules [Ding et al.,
2005; Grasberger et al., 2005; Vassilev et al., 2004]. This
and related examples demonstrate the significant impact
peptide inhibitors can have as tools for therapeutic vali-
dation and as stepping stones toward small molecule dis-
covery efforts [Sattler et al., 1997; Friberg et al., 2012].
Despite the many benefits of peptide ligand dis-
covery, it is important to note some of the challenges
that may need to be overcome when venturing into
peptide optimization. Peptides suffer from poor phys-
icochemical properties often due to their polar back-
bone and charged side groups [Tsomaia, 2015]. For
instance, the hydrogen bond donation capacity of the
amide proton has been shown to be a significant con-
tributor to the poor membrane permeability of small
peptides [Kwon and Kodadek, 2007; Tan et al., 2008].
Peptide ligands selected as starting points for optimiza-
tion may also incur issues of low affinity and poor
selectivity, making preliminary assay development and
characterization challenging. Additionally, natural
peptides are often substrates for proteases, and in the
case of in vivo studies, peptides can face rapid clearance
in the liver and kidneys [Tsomaia, 2015].
Fortunately, a range of strategies have been devel-
oped to overcome poor peptide properties. First, trunca-
tion studies to determine the minimal peptide sequence
required for binding and the use of an alanine scan
[Cunningham and Wells, 1989] can both provide insight
into the potential interaction hot spots of the PPI and
reduce the total molecular weight of these ligands,
which is crucial if cellular penetration is desired. Next,
replacing natural amino acids with non-natural ones
simultaneously provides an opportunity for potency
enhancement and reduces susceptibility to protease
degradation [Gentilucci et al, 2010]. For example,
D-amino acids are a commonly applied, non-natural
substitution in peptide optimization. Additionally, back-
bone N-methylation is able to both rigidify the peptide
conformation and improve permeability [Biron et al.,
2008]. Instituting conformational constraints is one strat-
egy to improve affinity by reducing the entropic penalty
of binding [Khan et al., 1998], and this premise is often
applied in the development of macrocyclic or stapled
peptide inhibitors [Bock et al., 2013]. Lastly, the avail-
ability of structural information for a specific target can
help guide which of these approaches for improving
ligand permeability may be most applicable.
Burgeoning efforts to better understand chro-
matin biology suggests a need for chemical tools to
help dissect the function of critical PPIs among
chromatin-associated proteins. Higher-order packag-
ing of DNA into chromatin within the nucleus is
dynamically regulated and requires exquisite coordi-
nation between the factors that direct this packaging
and those that require access to the underlying DNA
for replication, transcription, and repair [Wang et al.,
2007]. The core repeating unit of chromatin, known
as the nucleosome, contains approximately 147 base
pairs (bp) of DNA wrapped nearly twice around an
octamer of histone proteins. Extensive efforts in
chromatin-based research have shown that the
deposition of post-translational modifications (PTMs)
on histone and non-histone proteins is an essential
mechanism for recruiting the factors that regulate
replication and transcription [Strahl and Allis, 2000;
Bode and Dong, 2004; Huang and Berger, 2008;
Benayoun and Veitia, 2009; Delmore et al., 2011;
PEPTIDE TOOLS TO STUDY CHROMATIN 301
Drug Dev. Res.
Sadakierska-Chudy and Filip, 2015]. Commonly
described PTMs of histone tails include methylation,
ubiquitinylation, sumoylation, acetylation, crotonyla-
tion, butyrylation, ADP-ribosylation, and phosphory-
lation, although others have been discovered and
many more are likely to exist [Andrews et al., 2016].
Although an individual PTM might appear
minor in the context of the totality of chromatin reg-
ulation, these marks are central to the complex biol-
ogy of epigenetics. The simplistic view of this
regulation may be summarized as follows: PTMs are
deposited and removed by distinct enzymes (referred
to as “writers” and “erasers,” respectively) and ulti-
mately interpreted by proteins that bind to the mark
and mediate a biological effect (“readers”). Many of
these writers, readers, and erasers intricately connect
with one another to coordinate their functions, trig-
ger activities of the chromatin machinery, and indi-
rectly regulate gene transcription. The diversity of
both the types of modifications and their locations
yields an overwhelming number of potential messages
[Ernst et al., 2011] Despite rigorous examination, a
knowledge gap persists in our understanding of how
mechanistically many of these marks elicit a biologi-
cal response, and chemical probes can play a central
role in closing this gap. Herein, we detail current
efforts in peptidic and peptidomimetic tool develop-
ment for the chromatin PTM regulatory machinery.
We focus on available technologies for the prelimi-
nary assessment of peptide–protein interactions, the
evolving field of peptidomimetic inhibitor discovery
against these proteins, and the implications of these
studies for future small molecule efforts.
PRELIMINARY CHARACTERIZATION OF PEPTIDE–
PROTEIN INTERACTIONS
Prior to initiating a program to optimize a pep-
tidic inhibitor for a target of interest, a thorough knowl-
edge of the substrate preferences for that target can be
hugely insightful. Profiling protein–peptide interac-
tions via microarray platforms has had an enormous
impact on the characterization of chromatin-associated
protein ligands. Beyond simply better understanding
the binding preferences of a protein, the extensive
sequence selectivity data that microarrays provide con-
structs a strong preliminary SAR profile that may rap-
idly allow peptide truncation and ligand optimization
(Fig. 1). Moreover, a known peptide ligand for the
pocket of interest enables the development of assays to
efficiently screen compound collections or conduct
follow-up peptide SAR.
Microarray chips with libraries of histone peptides
affixed to a solid surface are capable of probing protein
affinity and selectivity with minimal cost associated and
material per chip [Uttamchandani and Yao, 2008].
Importantly, peptide microarrays are typically amenable
to libraries of hundreds of peptides, or even more with
the appropriate infrastructure, but significant synthetic
effort and time are required to synthesize, purify, and
Fig. 1. Microarray screening platform. Preliminary microarray profiling facilitates substrate and selectivity characterization along with spurring
subsequent assay development and inhibitor optimization. [Color figure can be viewed at wileyonlinelibrary.com]
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characterize the individual peptides for each library
[Rothbart et al., 2012]. An exceptional example of such
an approach comes from the Strahl group. They devel-
oped histone peptide microarrays labeled with >4000
peptides [Rothbart et al., 2012]. In brief, biotinylated
histone peptides decorated with variable PTMs are syn-
thesized and printed on a streptavidin coated glass slide.
Next, the slide is coated with a His- or glutathione S-
transferase (GST)-tagged target reader protein followed
by the addition of a fluorescently-labeled secondary anti-
body. Fluorescence confirms that the target protein is
bound and indicates a positive protein–peptide interac-
tion. Although spotting final peptides onto chips for
screening is relatively straightforward, careful design of
the peptide library and optimization of screening condi-
tions are critical to yield the information of interest.
When seeking to assign an endogenous ligand for
less well-characterized reader proteins, peptide librar-
ies require greater diversity in both the PTMs and his-
tone sequences. (Scott B. Rothbart et al., 2012) For
instance, the BAH domain of ORC1 was thought to
associate with chromatin based upon the reported
function of an orthologous domain in budding yeast
[Kuo et al., 2012]. To assess the validity of this hypothe-
sis, an 82 histone peptide library was probed with GST
labeled ORC1BAH and significant fluorescence was
observed for only H4K20me2-containing peptides.
This subsequently led to insights into a genetic disease
that features mutations adjacent to the ORC1 methyl-
lysine (Kme) binding site [Kuo et al., 2012]. In con-
trast, when seeking to better profile the binding selec-
tivity of a reader domain with a known substrate, a
diverse library designed around the substrate sequence
might be more informative and help to probe combina-
torial PTM effects [Rothbart et al., 2012].
In another example, the Strahl lab used their pep-
tide libraries to characterize the multivalent engagement
of UHRF1’s tandem tudor domain (TTD) and plant
homeodomain (PHD) with histone H3, residues 1–10
[Rothbart et al., 2013]. The TTD had previously been
shown to bind preferentially to H3 lysine 9 trimethyla-
tion (H3K9me3) [Rothbart et al., 2012], but secondary
profiling of the dual domain construct showed synergism
between TTD binding and the PHD domain’s recogni-
tion of residues 1–4 of H3. Moreover, the array profile
demonstrated that several PTMs on these four H3 N-
terminal residues disrupted UHRF1 binding. The exten-
sive combinations of PTMs available in the library
afforded rapid classification of UHRF1 binding prefer-
ences, and demonstrated the utility of peptide microar-
rays for elucidating multivalent binding of chromatin-
associated proteins. Recent efforts to exploit multiva-
lency in ligand development for chromatin reader pro-
teins indicate that inhibiting these broader interfaces is
a tractable strategy [Tanaka et al., 2016; Waring et al.,
2016]. Consequently, profiling these types of multi-
domain proteins via peptide arrays might shift prelimi-
nary ligand discovery efforts to focus on disrupting both
pockets to exploit the synergy of such an interaction.
An analogous peptide array strategy applies
“SPOT” synthesis to assess protein target binding to
histone PTMs. In this approach, a peptide library can be
synthesized directly on a cellulose membrane using
standard peptide synthesis methodology and Fmoc-
protected amino acids [Nady et al., 2008; Muller and
Muir, 2015]. Following synthesis, SPOT arrays are incu-
bated with epitope tagged proteins of interest and ana-
lyzed for peptide binding by either fluorescence-based
or immunological detection [Nady et al., 2008; Muller
and Muir, 2015]. The SPOT blot platform offers certain
advantages over conventional peptide microarrays. First,
direct synthesis on the cellulose membrane eliminates
the need for purification of individual biotinylated pepti-
des necessary for the assembly of microarrays [Toepert
et al., 2003; Nady et al., 2008; Muller and Muir, 2015].
Second, thousands of modified peptides can be quickly
and efficiently synthesized in parallel on a single
SPOT array enabling the inclusion of any of the 100 plus
histone marks in a singular or combinatorial fashion
[Muller and Muir, 2015]. Importantly, screening
unpurified peptides in this strategy does raise concerns
regarding the potential build-up of synthetic by-
products and the risk of false positive results, but this
issue can be addressed via follow-up off-cellulose
orthogonal assays to characterize the interaction.
Among the most prominent applications of SPOT
array-based screening is the interrogation of chromatin-
associated proteins to identify modification-specific and
sequence-specific histone interactions. One impressive
study describes a global, systematic analysis of bromodo-
main specificity for acetylated lysine-containing peptides
[Filippakopoulos et al., 2012]. Numerous SPOT arrays
were assembled, ranging from arrays decorated with sin-
gly acetylated peptides to acetylated peptides flanked by
neighboring PTMs to polyacetylated peptides. These
studies demonstrated the preference of bromodomains
for poly-acetylated peptides over mono-acetylation [Fili-
ppakopoulos et al., 2012]. Another comprehensive study
involved characterizing the sequence specificity of the
Kme reader chromobox homolog (CBX) proteins for
their cognate methylated peptides [Kaustov et al., 2011].
Using two SPOT arrays spanning histone H3 residues
3–15 and 21–33 with H3K9me3 or H3K27me3, respec-
tively, peptides were assembled such that every residue
in the sequence was systematically mutated to each of
the twenty natural amino acids, yielding a total of 260
peptides per array. Representative members of both the
HP1 (CBX3) and Polycomb (CBX7, CBX8) sub-families
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of CBX proteins were evaluated for their binding specif-
icity, providing a wealth of peptide SAR. While CBX3
bound only H3K9me3 peptides, CBX8 was selective for
H3K27me3 peptides and CBX7 bound methylated pep-
tides on both arrays. Conserved recognition of an
“ARKme3S” motif present in both sequences was
shared across all CBX proteins, yet little sequence spe-
cificity was observed for other regions of the peptides
[Kaustov et al., 2011]. The specificity determinants char-
acterized by this study were critical to the development
of potent peptidomimetic CBX inhibitors and ultimately
led to a chemical probe for the Polycomb CBXs [Simha-
dri et al., 2014; Stuckey et al., 2016].
While peptide microarrays have been most exten-
sively applied to reader proteins of PTMs, they are cer-
tainly also amenable to substrate profiling of histone
modifying-enzymes. Thermofisher Scientific, Millipore
and Epicypher have all developed effective profiling
platforms for these enzymes which can deliver vast
amounts of information regarding substrate selectivity
and the contextual effects of other PTMs. Similarly,
rigorous examination of detection conditions for these
platforms is critical [Rothbart et al., 2012; Cornett
et al., 2016], but these approaches can rapidly inform
efforts aimed at understanding protein function and
selectivity.
Assigning endogenous ligands to chromatin-
associated proteins can illuminate novel biology and lay
a solid foundation for future peptide-to-probe optimiza-
tion. Peptide microarrays yield information on consen-
sus binding sequences and can provide initial peptide
SAR, help to inform peptide truncation plans, identify
key residues for modification, and suggest hotspot resi-
dues. Moreover, knowledge of the endogenous ligand or
a more potent analog may facilitate construction of an
assay infrastructure to pursue more extensive screening
campaigns. Thus, such peptide technologies inform bio-
logical hypotheses and can help to rapidly launch chemi-
cal probe development efforts.
PURSUING PEPTIDIC PROBES OF KME READERS
Although early efforts in peptidic ligand develop-
ment against chromatin-associated proteins included
inhibitors of the histone deacetylase (HDAC) enzyme
class [Montero et al., 2009; Olsen and Ghadiri, 2009],
this work followed early successes in small molecule
inhibitor development. Thus, we focus here on the
development of peptidomimetic ligands targeting the
less well-studied Kme readers to illustrate many of the
advantages of utilizing peptidic starting points for the
efficient targeting of PPIs in the study of chromatin
regulation. Our own early small molecule screening
campaigns for Kme reader proteins were met with
some limited success, yet led to the first-in-class Kme
reader chemical probe, UNC1215 [James et al., 2013].
However, the broad surface-groove binding modes of
many Kme readers classify them as “undruggable”
[Hopkins and Groom, 2002]. Bearing in mind that such
exposed interfaces are historically rife with failed
attempts at small molecule drug discovery, we and others
pursued peptidomimetic optimization as a rational alter-
native for probe discovery.
In the development of Kme reader inhibitors, we
were faced with a set of peptide-specific challenges to
overcome. First, many Kme readers bind methylated
histone peptides with affinities between 10 and 40 mM,
and such low potencies can be problematic for assay
development and early SAR [Botuyan et al., 2006; Guo
et al., 2009; Wigle et al., 2009; Kaustov et al., 2011]. Sec-
ond, many Kme readers of interest recognize the
trimethyl-lysine (Kme3) mark. Quaternary amines gen-
erally have poor passive membrane permeability, limit-
ing their application in cellular studies [Stuckey et al.,
2016]. Additionally, the peptide backbone is likely to
limit permeability due to the hydrogen bond donating
capacity of the amide protons [Goodwin et al., 2001;
Tan et al., 2008]. Third, the length of many methylated
histone peptides known to interact with Kme reader
domains is typically 10–20 residues [Guo et al., 2009; Xu
et al., 2010; Kaustov et al., 2011; Qin et al., 2013]. Opti-
mization efforts thus need to address truncating these
ligands while improving their affinities and properties,
as histone peptides are also generally poly-cationic and
contain other undesirable functional groups for cellular
efficacy (guanidine, primary amides, etc.). Finally, deriv-
atization of the endogenous histone ligand may result in
inhibitors that are naturally non-selective and bind mul-
tiple reader proteins.
Targeting the Polycomb CBX proteins, all of which
contain a conserved N-terminal chromodomain respon-
sible for Kme3 binding, exemplifies many of the chal-
lenges associated with Kme peptide optimization, but
also demonstrates the successful use of peptidomimetic
inhibitors to expand the ligandable proteome [Di Croce
and Helin, 2013]. The five Polycomb CBX proteins
(CBX2, 24, 26, 27, and 28) recognize H3K27me3
and serve as critical, but mutually exclusive, components
of canonical Polycomb Repressive Complex 1 (PRC1), a
key regulator of transcriptional programs. CBX7 is per-
haps the best studied Polycomb paralog, and efforts
have been focused on ascertaining its potential as a ther-
apeutic target due to its oncogenic role in several can-
cers and its effects in mediating embryonic stem cell
self-renewal [Bernard et al., 2005; Yap et al., 2010;
Klauke et al., 2013; Shinjo et al., 2014]. We and others,
therefore, sought a chemical toolbox to probe CBX, or
more specifically CBX7, function. Like the majority of
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Kme reader proteins, the CBX7 chromodomain contains
an aromatic cage that recognizes Kme3 predominantly
through p-cation interactions [Kaustov et al., 2011];
however, the formation of the aromatic cage of CBX7
seemingly requires the binding of a methylated peptide
to form a fourth antiparallel beta sheet, indicating the
necessity of the surrounding sequence for Kme3
recognition [Kaustov et al., 2011; Stuckey et al., 2016].
Peptide ligands lend themselves to this induced-fit
mode of binding as they are capable of making the
critical backbone hydrogen bonds that are required to
mediate CBX7 folding.
Pioneering CBX7 peptidic inhibitor exploration
began in the Hof group utilizing a SETDB1 peptide
shown to have higher in vitro potency for CBX7 than
the native H3K27me3 peptide [Kaustov et al., 2011].
This work led to a set of 5-mer peptide inhibitors with
sub-micromolar affinity for CBX7 [Simhadri et al.,
2014]. The most potent and selective CBX7 inhibitor
(Kd5 200 nM; 10-fold and 1.5-fold selective over
CBX8 and CBX4, respectively) retained the Kme3, ala-
nine, and phenylalanine residues of the SETDB1 pep-
tide, yet key alterations at other positions allowed for a
significant increase in potency (Compound 1, Fig. 2A).
Substitution of a propanediol group for serine likely
preserved key hydrogen bond donors that interact with
a glutamate residue in CBX7, while introduction of a
cyclopentylalanine residue highlighted a preference for
more hydrophobic residues at the position occupied by
an arginine in the histone sequence. Finally, installation
of a para-(methoxycarbonyl)benzamide group at the N-
terminus fared best out of many well tolerated para-
substituted benzyl substituents [Simhadri et al., 2014].
Parallel efforts in our group similarly began with
optimization of the SETDB1 peptide, but we instead
focused initially on tertiary amine replacements for the
Kme3 to simultaneously improve affinity and perme-
ability [Stuckey et al., 2016]. Our efforts culminated in
the discovery of UNC3866 (Fig. 2B), the first cellular
chemical probe for CBX Polycomb chromodomains.
While UNC3866 retains many of the structural fea-
tures of compound 1, replacement of the Kme3 with a
diethyl-lysine was crucial for cellular efficacy. More-
over, extensive SAR around the N-terminal benzamide
position demonstrated that this region added dramatic
potency enhancements through key hydrophobic con-
tacts when substitutions were made at the para-
position. A potential explanation for the significance of
this position was posed by molecular dynamics simula-
tions which suggested the N-terminus as the first point
of contact between histone H3 and CBX7,which in
turn initiates the induced-fit mode of binding. Surface
plasmon resonance (SPR) studies further supported
this hypothesis by demonstrating that the rigidity and
complimentary hydrophobicity of the cap enhances
association, as opposed to dissociation, rates. Thus, the
Fig. 2. CBX peptidomimetic inhibitors. (A) A preliminary peptidomimetic ligand of the PRC1 CBXs demonstrated nanomolar in vitro
potency and was achieved via truncation and incorporation of non-natural modifications. (B) Replacement of the Kme3 with diethyl-lysine
and optimization of the N-terminal cap furnished a cellularly active chemical probe, UNC3866. (C) Replacement of the central alanine with
valine led to a new strategy for homolog specificity for CBX6 within the CBX family.
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induced-fit binding hypothesis complimented ligand
property optimization to facilitate the discovery of a
cellularly efficacious peptidomimetic chemical probe.
Careful characterization of UNC3866’s selectivity
profile led to the discovery that, despite high selectivity
outside of the chromodomain family and versus the HP1
CBX domains (CBX1,23, and25), UNC3866 did have
modest affinity for all of the Polycomb chromodomains
and off-target affinity for the CDY chromodomain fam-
ily. Given that these chromodomains have all been
shown to recognize H3K27me3, this result is unsurpris-
ing, but the nearly 10-fold selectivity for CBX4 and 27
over other Polycomb CBXs was interesting and suggests
some differences in the interaction interface that may
yield improved selectivity in second generation ligands.
Importantly as tools for Polycomb biology, these ligands
do not bind the other known H3K27me3 reader in this
pathway, embryonic ectoderm development (EED),
which is a WD40 domain Kme reader. By targeting the
subtle differences at the CBX-ligand interface, selective
peptidomimetic compounds have been developed for
CBX6, a Polycomb chromodomain that does not yet
have a well-defined function [Milosevich et al., 2016].
These efforts capitalized on the slightly larger alanine
binding pocket of CBX6 versus CBX4 and 27 by
substituting the alanine with a valine to deliver a pepti-
domimetic ligand that is 6- to 20-fold selective for CBX6
over the other Polycomb CBXs, and 90-fold selective
over CBX1 (Compound 2, Fig. 2C). Unfortunately, this
substitution does not improve CBX6 affinity and these
ligands retain only around 1 mM affinity for CBX6, while
differentially losing affinity for other Polycomb CBX
domains tested. Additionally, CBX2 and 28 possess
identical alanine binding pockets to CBX6 but experi-
enced a loss of affinity similar to that of CBX4 and 27,
suggesting other selectivity determinants outside of this
pocket that are not yet known. The challenge moving
forward is taking a non-selective peptidic scaffold and
incorporating non-peptide functionalities to facilitate
selective and potent chemical probe development within
the Polycomb CBX family. The multiple co-crystal struc-
tures obtained during these initial efforts should prove
invaluable to this process [Stuckey et al., 2016].
Although UNC3866 has been successfully
applied as a cellular chemical probe and its initial
mouse PK following intraperitoneal administration is
promising, this compound has fallen short of finding
utility in an in vivo context owing to poor cell perme-
ability. The modest cellular potency of UNC3866
(EC50 7 lM) which is permeability limited illustrates
the remaining challenges in developing an in vivo
chemical probe using this template [Stuckey et al.,
2016]. Ongoing studies are aimed at further enhancing
permeability, target affinity, and the utilization of in
vivo appropriate delivery systems to overcome these
issues.
MINING PEPTIDE CHEMICAL SPACE VIA
COMBINATORIAL CHEMISTRY
The extensive effort required to investigate struc-
tural hypotheses for chromodomain inhibition is indica-
tive of the challenges inherent in systematic peptide
optimization. When carried out via solution phase
synthesis, peptide SAR is costly, time-consuming, and
often fails to discover synergistic modifications. Design-
ing selective compounds from a modestly selective, large
scaffold is not always straightforward and often comes at
the expense of potency or permeability. Fortunately, the
past three decades have witnessed the advent of impres-
sive combinatorial technologies to address these very
issues. Applying combinatorial chemistry to the optimi-
zation of peptidomimetic ligands affords a strategy for
the rapid discovery and optimization of peptidic and
peptidomimetic ligands while interrogating hundreds-
to-thousands of key structural hypotheses with minimal
effort and cost.
Combinatorial chemistry provides an economi-
cally efficient route to mine chemical space via the
rapid creation and screening of libraries on the order of
104–1012 compounds. Unlike small molecules, peptides
are well-suited to traditional combinatorial methodolo-
gies due to their efficient chemistries, modular assem-
bly, and straightforward structural deconvolution via
tandem mass spectrometry. Additionally, peptides are
uniquely capable of harnessing the cellular machinery
to develop vast phage and mRNA display-based librar-
ies. In applying combinatorial peptide assembly, the
advantages are by no means limited to hit discovery as
combinatorial hit optimization can also be achieved via
rapid exploration of targeted chemical space [Aina
et al., 2007; Gao et al., 2015]. Mining targeted chemical
space in turn informs an understanding of the struc-
tural requirements for binding and yields extensive
SAR. Ultimately, a successful combinatorial platform
for peptidic ligand optimization requires an informed
library design and a screening infrastructure to reap
the benefits of this technique without falling prey to its
pitfalls.
Multiple groups have previously explored combi-
natorial peptide optimization focused on improving
affinity. Where less advancement has occurred is in the
application of combinatorial chemistry to improve com-
pound properties and deliver biologically relevant and
selective chemical probes. Rationally designed combina-
torial libraries and appropriate screening strategies are
likely to enable the identification of ligands with
improved physicochemical properties. Furthermore, the
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amenability of combinatorial libraries to multiple rounds
of screening facilitates a target class screening effort to
yield selectivity and affinity information prior to struc-
tural deconvolution [Barnash et al., 2016].
The successful use of a combinatorial strategy to
facilitate peptide-to-peptidomimetic optimization can
be seen in our development of ligands for the central
Kme reader of Polycomb repressive complex 2
(PRC2), EED [Barnash et al., 2017]. PRC2, which con-
tains three core components, enhancer of zeste homo-
log 1 or 2 (EZH1/2), EED, and suppressor of zeste 12
(SUZ12), coordinates the methylation of H3K27 via
the enzymatic activity of EZH1 or 22. EED binds and
interprets the product of PRC2 activity, H3K27me3,
which in turn allosterically stimulates EZH2 methyl-
transferase activity mediating propagation of this PTM
[Margueron et al., 2009]. Starting with a five-residue
non-histone methylated peptide (Kd 10 mM), the
design, synthesis, and screening of two combinatorial
libraries paired with traditional SBD resulted in a 10-
fold more potent EED ligand with a reduced number
of hydrogen bond donors and a lower charge state.
Ultimately, the final ligand, UNC5115, has a molecular
weight under 600 Da, has a charge state of 12,
includes only three hydrogen bond donors, and con-
tains only a single natural amino acid (Fig. 3A). While
methylated proteins that bind to the EED reader
pocket are known to stimulate PRC2 methyltransferase
activity, our peptidomimetic ligands inhibit PRC2
methylation of an H3K27 peptide. Since these inhibi-
tors were inactive against EED aromatic cage mutants
and they were shown to compete with H3K27me3, we
concluded that they likely function allosterically by dis-
rupting the stabilization of a critical EZH2 a-helix that
facilitates opening of the enzyme’s substrate binding
channel. Consequently, PRC2 retains basal activity but
is not stimulated upon ligand binding. Disruption of
the Kme reader function of EED is consequently a via-
ble strategy for targeting PRC2, and interestingly, the
effects are unlikely to be identical to those of previously
published EZH2 inhibitors due to the retention of
basal methyltransferase activity.
In addition to EED ligand development, we
exploited the ability of on-bead libraries to be screened
repeatedly to pursue a target class screening strategy,
with the intention of repurposing UNC3866 to discover
high affinity ligands versus the chromodomains of the
CDY family. After the synthesis of a UNC3866 deriva-
tive library and a preliminary negative selection, we
screened our biased library against the target chromodo-
main, CDYL2, and employed competitor exchange
kinetics to selectively isolate higher affinity ligands than
UNC3866. Subsequent homologous chromodomain
negative selections against the CDYL2 binding beads
removed non-selective ligands, leading to the final
isolation of ligands with unique potency and selectivity
profiles as compared to UNC3866. UNC4991 is a sub-
micromolar ligand of the CDYL chromodomains that
demonstrates the importance of the N-terminal residue
in mediating chromodomain potency and selectivity
[Barnash et al., 2016]. Moreover, the library hits demon-
strate minimal tolerance to alteration at the alanine,
lysine, and serine positions yielding important insights
into the requirements for peptidomimetic binding
across chromodomains. Although these ligands have not
yet been exploited to discern novel CDYL2 biology, we
anticipate continued optimization and expanded interest
in CDYL proteins will greatly enhance the impact of
this series of ligands [Liu et al., 2017]. Moreover, this
combinatorial strategy is readily applicable to other
chromodomain-containing proteins and can rapidly
yield ligands of novel selectivity and affinity against new
targets.
The dependence of hit deconvolution on sequenc-
ing efficiency in one-bead-one-compound libraries lim-
its the utility of this approach for interrogating larger
peptides, and screening libraries of more than a few
million compounds is practically quite challenging for
most academic settings. Consequently, alternative pep-
tide library technologies have emerged over the past
three decades to interrogate larger libraries [McCaff-
erty et al., 1990; Hanes and Pl€uckthun, 1997; Roberts
and Szostak, 1997]. These display technologies (ribo-
somal, phage, and mRNA) all apply DNA sequencing,
not peptide sequencing, for final hit deconvolution.
Moreover, screening of the libraries can be conducted
on a much smaller scale due to the homogenous nature
of the selection platform which typically includes an
affinity enrichment step for protein-bound peptide
ligands. Suga and co-workers discovered a mechanism-
based, isoform selective SIRT2 macrocyclic peptide
inhibitor through mRNA display [Morimoto et al.,
2012]. Their library incorporated three non-natural
amino acids including an acetyl-lysine mimetic (trifluor-
oacetyl-lysine) that dramatically reduces the diacylation
reaction rate and a-N-(2-chloroacetyl)-L-tyrosine or a-
N-(2-chloroacetyl)-D-tyrosine to covalently react with
nucleophilic residues in or near the catalytic site. Final
ligands derived from these efforts exhibited affinity in
the single digit nanomolar range, demonstrating the
utility of using combinatorial libraries to rapidly develop
potent and selective ligands against challenging targets.
Ultimately, display techniques substantially expand the
diversity achievable with large peptide libraries, but
they are currently hindered by the limitations of genetic
encoding; however, significant effort has been invested
to address this issue and engineer technologies to incor-
porate PTM-mimetic amino acids [Guo et al., 2008;
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Morimoto et al., 2012; Kawakami et al., 2013; Knight
and Cropp, 2015; Elsasser et al., 2016]. It is likely that
the use of such display technologies will greatly increase
as improvements are made to the available chemical
diversity.
PEPTIDE AND SMALL MOLECULE
COMPLEMENTARITY FOR LIGAND DEVELOPMENT
Our own efforts in peptidomimetic inhibitor
development yielded significant advances in the under-
standing of PRC1 chromodomain function, chromodo-
main family selectivity, and allosteric regulation of
PRC2. Pursuing such peptidomimetics is advantageous
in an academic setting where diversity oriented synthe-
sis of compound libraries would be both high risk and
prohibitively expensive; yet, limited cell permeability
and in vivo efficacy restrict the current use of these
peptidomimetic ligands toward understanding chroma-
tin regulation at an organismal level. Peptidomimetics
are, however, advantageous as a window of insight into
the ligandability of PPIs. Additionally, they are easily
derivatized to facilitate new assay methodologies as our
sights shift back to small molecule discovery.
Our own preliminary efforts at small molecule
discovery against the malignant brain tumor (MBT)
family of Kme readers were distinctly biased toward
peptidic fragments which evolved into small molecule
Kme mimetics off of an aromatic core [Herold et al.,
2011; Herold et al., 2012]. These ligands were
intended to bind analogously to the native Kme but
with conformational constraints and improved con-
tacts in and around the targeted aromatic cage.
Cross-screening of these compounds within the Kme
reader and methyltransferase target classes has led to
some success, but has often resulted in modestly
potent ligands [James et al., 2013; Ma et al., 2014;
Perfetti et al., 2015; Robaa et al., 2016; Wagner
et al., 2016]. Elaborating on the current peptidomi-
metic scaffolds that target chromatin regulatory pro-
teins might spur innovative strategies to evolve
peptidomimetics toward small molecule-like chemical
Fig. 3. EED inhibitors. (A) UNC5115 is a peptidomimetic ligand of EED that was optimized via paired combinatorial chemistry and SBD.
(B) Small molecule inhibitors of EED restructure Trp364 and Tyr365 of EED’s aromatic cage (black, PDB 5GSA) as compared to the binding
mode of methylated peptides (PDB 5HYN). The small molecule inhibitors (C) A-395 and (D) EED226 are structurally divergent but induce
similar binding modes in EED.
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space. Known mimetics of peptide cores have also
not been explored in this context, and future efforts
may benefit from assessing the amenability of these
peptides to such replacements [Lao et al., 2014; Bhardwaj
et al., 2016; Craven et al., 2016; Watkins et al., 2017].
Recent efforts targeting the preformed aromatic
cage of EED are suggestive of a new strategy for
small molecule antagonism of Kme reader domains
[He et al., 2017; Qi et al., 2017]. The reported EED
chemical probes, published simultaneously by AbbVie
and Novartis, completely restructure the “open” aro-
matic cage of EED resulting in analogous binding
modes. In both structures, the tryptophan of the cage
(Trp364) is flipped out toward the protein surface
due to the movement of tyrosine 365 upon binding
(Fig. 3B). This movement is facilitated by compensa-
tory ligand cation-p interactions with the two tyro-
sines of the aromatic cage in the case of A-395 (Fig.
3C), whereas EED226 (Fig. 3D) appears to form a
network of p stacking interactions through its elec-
tron deficient aromatic core. The binding mode of
the latter compound suggests the possibility of target-
ing other Kme reader proteins with small molecules
in a similar fashion. Unlike A-395, EED226 is
completely void of chiral centers and its structure is
almost fragment-like, yet its affinity for EED is low
nanomolar. Moreover, EED226 is the first Kme
reader chemical probe to lack a discernible Kme
mimetic due to replacement of this moiety with an
electron deficient aromatic ring system.
These small molecule EED modulators exem-
plify conversion of the “undruggable” into the drug-
gable via the creation of an induced-fit pocket. The
implications of these successes are that, given an
appropriate small molecule library, motifs capable of
restructuring aromatic cages could be reapplied in a
target class screening effort to reassess the small mol-
ecule ligandability of Kme reader proteins. Accord-
ingly, the challenge lies in developing and pursuing a
more appropriate chemical space to induce rear-
rangement of aromatic cages. The success of
EED226 suggests that electron deficient aromatic
fragments represent a promising starting point for
library design and inclusion in peptide frameworks
for ligand discovery. Perhaps this motif will represent
a privileged scaffold for Kme reader antagonists?
CONCLUSIONS
Modulation of chromatin compaction via PTM
deposition and removal requires exquisitely con-
trolled protein machinery. Multiprotein complexes,
such as PRC1 and PRC2, directly regulate individual
marks and indirectly regulate numerous PTMs, but
the complexity of their biology prevents molecular
and genetic techniques from elucidating a compre-
hensive understanding of their function. Moreover,
teasing apart the individual contributions of specific
domains remains an even more daunting task when
solely relying on these traditional approaches.
The growing trend toward targeting chromatin-
modifying proteins demonstrates the advantages of
chemical probes for interrogating domain function.
Kme readers are a fascinating target class that exempli-
fies the challenge of interrogating PPIs with chemical
probes. The disruption of the surface groove binding of
Kme readers to their cognate histone peptides via high-
throughput small molecule hit discovery has been only
modestly successful to date [He et al., 2017; Huang
et al., 2017; Li et al., 2017; Lingel et al., 2017; Qi et al.,
2017]. In contrast, optimized peptidomimetic inhibi-
tors are a viable alternative for cellular chemical probe
discovery with known challenges to be overcome. Pep-
tides offer several advantages including a rational start-
ing point for ligand optimization, simple chemistry, and
complementary geometric and structural features to
target large protein surfaces. In contrast, improving the
potency, selectivity, and physicochemical properties of
peptide ligands in order to achieve high-quality probes
that engender a biologically relevant endpoint can be
challenging. Strategies that enable the multi-parameter
optimization of peptidic ligands hold the potential to
drastically increase the rate of chemical probe discov-
ery for chromatin-associated machinery, while merging
on-bead peptide ligand optimization with the evolution
of small molecules will likely also be advantageous.
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